Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

Changhoon Yoo, Do-Youn Oh, Hye Jin Choi, +8

Journal for ImmunoTherapy of Cancer

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Yelena Y. Janjigian, Salah-Eddin Al-Batran, Zev A. Wainberg, +23

New England Journal of Medicine

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, +18

Journal for ImmunoTherapy of Cancer

Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group

Changhoon Yoo, Hyeon-Su Im, Kyu-pyo Kim, +13

Therapeutic Advances in Medical Oncology

Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer

Hye Rim Ha, Do-Youn Oh, Tae‐Yong Kim, +10

PLoS ONE

Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression

Yoonjin Kwak, Tae-Yong Kim, Soo Kyung Nam, +10

The Oncologist

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

Hye Sook Han, Bum Jun Kim, Hee‐Jung Jee, +16

Therapeutic Advances in Medical Oncology